Barclays Upgrades Celldex Therapeutics to Overweight, Raises Price Target to $45

Benzinga Newsdesk www.benzinga.com Positive 93.2%

Neg 0% Neu 0% Pos 93.2%

Barclays analyst Etzer Darout upgrades Celldex Therapeutics (NASDAQ:CLDX) from Underweight to Overweight and raises the price target from $24 to $45.